Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine® Personalized Adult Stem Cell Therapy

Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using StemSpine® Personalized Adult Stem Cell Therapy
Commercial Stage Regenerative Medicine Company Expands it's Hold "Ready to Commercialize" Autologous Bone Marrow Procedures
News provided by
Share this article
Share this article
PHOENIX, March 4, 2021 /PRNewswire/ -- (OTC -  CELZ) Creative Medical Technology Holdings announced today a publication in the pre-print server SSRN describing data from its first 15 patients treated in a clinical trial evaluation perispinal injection of bone marrow cells in patients with disc degenerative disease.  Evaluation of patients at 30,60 90, 180, and 360 days revealed significant improvement in mobility and reduction in pain score .  The mean pain changed from 8.9 at baseline to 4.3 at 30 days and sustained to 1.8 at 6 months and 1.3 at 12 months with a gradual reduction in overall pain medication utilization guided by their healthcare team. No serious adverse effects were noted with some short-term bruising in two patients at the harvest site and no long term adverse events where reported related to the procedure. 

Related Keywords

Phoenix ,Arizona ,United States ,American ,Timothy Warbington ,Amit Patel ,Exchange Commission ,Founder Of The Company ,Creative Medical Technology Holdings Inc ,Creative Medical Technology Holdings ,Board Member ,United States Patent ,Medical Technology Holdings ,Inc ,பீனிக்ஸ் ,அரிசோனா ,ஒன்றுபட்டது மாநிலங்களில் ,அமெரிக்கன் ,அமித் படேல் ,பரிமாற்றம் தரகு ,நிறுவனர் ஆஃப் தி நிறுவனம் ,படைப்பு மருத்துவ தொழில்நுட்பம் ஹோல்டிங்ஸ் இன்க் ,படைப்பு மருத்துவ தொழில்நுட்பம் ஹோல்டிங்ஸ் ,பலகை உறுப்பினர் ,ஒன்றுபட்டது மாநிலங்களில் காப்புரிமை ,மருத்துவ தொழில்நுட்பம் ஹோல்டிங்ஸ் ,இன்க் ,